Full Press Release Details
Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities Lead Asset (ZW25) Demonstrating Promising Clinical Activity; Growing Number of Pharmaceutical Partners Validate Bispecific Antibody Technology.
ZYME
Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities Lead Asset (ZW25) Demonstrating Promising Clinical Activity; Growing Number of Pharmaceutical Partners Validate Bispecific Antibody Technology
Key Takeaway: Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities Lead Asset (ZW25) Demonstrating Promising Clinical Activity; Growing Number of Pharmaceutical Partners Validate Bispecific Antibody Technology
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers